相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages
John de Groot et al.
NEURO-ONCOLOGY (2020)
VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours
Eric Song et al.
NATURE (2020)
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma
Sangeeta Goswami et al.
NATURE MEDICINE (2020)
Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes
Ekaterina Friebel et al.
CELL (2020)
Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells
Florian Klemm et al.
CELL (2020)
Evaluation of glioblastoma tumor microenvironment after treatment with pembrolizumab.
Nazanin Majd et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon et al.
JAMA ONCOLOGY (2020)
Mechanisms and therapeutic implications of hypermutation in gliomas
Mehdi Touat et al.
NATURE (2020)
MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence
Radhika Mathur et al.
NEURO-ONCOLOGY (2020)
PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?
Mustafa Khasraw et al.
CLINICAL CANCER RESEARCH (2020)
Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells
Ganesh Rao et al.
CLINICAL CANCER RESEARCH (2020)
Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration
Martina Ott et al.
JCI INSIGHT (2020)
Brain immunology and immunotherapy in brain tumours
John H. Sampson et al.
NATURE REVIEWS CANCER (2020)
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
Neal Ready et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Kurt A. Schalper et al.
NATURE MEDICINE (2019)
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Timothy F. Cloughesy et al.
NATURE MEDICINE (2019)
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Junfei Zhao et al.
NATURE MEDICINE (2019)
Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors
Lea Berland et al.
JOURNAL OF THORACIC DISEASE (2019)
Cancer stemness, intratumoral heterogeneity, and immune response across cancers
Alex Miranda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma
Yochai Wolf et al.
CELL (2019)
1192OAssociation of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158
A Marabelle et al.
ANNALS OF ONCOLOGY (2019)
KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC
C. Langer et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
A Phase III Randomized Study of Nivolumab/Ipilimumab vs Nivolumab for Previously Treated Stage IV Squamous Cell Lung Cancer
L. Bazhenova et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Longitudinal molecular trajectories of diffuse glioma in adults
Floris P. Barthel et al.
NATURE (2019)
ATIM-27. TUMOR MUTATIONAL BURDEN PREDICTS RESPONSE TO ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF TRANSCRIPTIONAL AND IMMUNOLOGICAL CORRELATES
Matthias Gromeier et al.
NEURO-ONCOLOGY (2019)
Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation
Tom B. Davidson et al.
CLINICAL CANCER RESEARCH (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
T-cell Dysfunction in Glioblastoma: Applying a New Framework
Karolina I. Woroniecka et al.
CLINICAL CANCER RESEARCH (2018)
T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
Karolina Woroniecka et al.
CLINICAL CANCER RESEARCH (2018)
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
Georgina V. Long et al.
LANCET ONCOLOGY (2018)
Recurrent Glioblastoma Treated with Recombinant Poliovirus
Annick Desjardins et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking
David Taggart et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
Franz L. Ricklefs et al.
SCIENCE ADVANCES (2018)
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Sydney R. Gordon et al.
NATURE (2017)
PD-L1 expression and prognostic impact in glioblastoma
Edjah K. Nduom et al.
NEURO-ONCOLOGY (2016)
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
Eric Bouffet et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma
Lee A. Wheeler et al.
NEURO-ONCOLOGY (2016)
PD-L1 expression in human cancers and its association with clinical outcomes
Xin Wang et al.
ONCOTARGETS AND THERAPY (2016)
Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial
Manfred Westphal et al.
LANCET ONCOLOGY (2013)
分享论文
